<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesJohn S. Welch, Timothy J. Ley, Allegra A. Petti et al.|New England Journal of Medicine|2016Cited by 783
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Nicholas J. Short et al.|The Lancet Haematology|2020Cited by 330
Mutation Clearance after Transplantation for Myelodysplastic SyndromeEric J. Duncavage, Matthew J. Walter, Meagan A. Jacoby et al.|New England Journal of Medicine|2018Cited by 121
A global study for acute myeloid leukemia with <i>RARG</i> rearrangementHong‐Hu Zhu, Suning Chen, Ya‐Zhen Qin et al.|Blood Advances|2023Cited by 26
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myelomaErica K. Barnell, Lukas D. Wartman, Zachary L. Skidmore et al.|Blood Advances|2022Cited by 19